Key Findings:  Complete remission (Crohn's Disease Activity Index (CDAI) score, 100) was observed in 10 of 11 subjects in the cannabis group and 4 of 10 in the placebo group. Three patients in the cannabis group were weaned from steroid dependency. Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects.
Type of Study:  Double Blind Clinical Trial
Study Sample Size:  21
Study Result:  Positive
Study Location(s):  Israel
Year of Pub:  2013
Cannabinoids Studied:  Tetrahydrocannabinol (THC)
Phytocannabinoid Source:  Cannabis Flower derived
Chemotype:  Chemotype I
Sub-Ratio: 1:0 (THC:CBD)
Dosage: THC (115 mg) or placebo 2x/day for 8 weeks
Route of Administration:  Inhalation